Inclusion criteria:

          -  At least 18 years of age

          -  Advanced solid tumors including lymphomas for which no standard alternative therapy is
             available (escalation phase).

          -  Advanced melanoma (Stage IIIB-C or Stage IV, anti-PD-1/PD-L1 treated or not) or
             anti-PD-1/PD-L1 not treated advanced Head and Neck Squamous Cell Cancer or
             anti-PD-1/PD-L1 not treated Advanced Cutaneous Squamous Cell Cancer where no other
             alternative treatment option exists (expansion phases).

          -  Minimum 3 lesions enrollment.

          -  Injectable disease (i.e., suitable for direct intratumoral injection based on the dose
             level volume of each cohort and cumulative lesion size; according to the
             investigator's judgement).

          -  A lesion amenable for additional tumor biopsy.

          -  Patients with measurable disease according to the Response Evaluation Criteria in
             Solid Tumors (RECIST) 1.1 criteria.

          -  Life expectancy more than 3 months.

          -  Willingness to provide mandatory tumor biopsy.

          -  Male and female patients who agree to use effective contraceptive methods.

          -  Signed informed consent.

        Exclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance score >1.

          -  Significant and uncontrolled concomitant illness that would adversely affect the
             patient's participation in the study.

          -  Any prior organ transplantation.

          -  History within the last 5 years of an invasive malignancy other than the one treated
             in this study, with the exception of resected basal or squamous-cell skin cancer or
             carcinoma, in situ of cervix or other local tumors considered cured by local
             treatment.

          -  History of unresolved viral hepatitis; systemic immune suppression including acquired
             immunodeficiency syndrome (AIDS) related illnesses or human immunodeficiency virus
             (HIV) disease requiring antiretroviral treatment.

          -  Prior splenectomy.

          -  New and progressive brain lesions.

          -  Poor bone marrow reserve resulting in low blood cell count.

          -  Poor liver and kidney functions, abnormal coagulation tests.

          -  Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
             required treatment with systemic immunosuppressive treatments.

          -  Maintenance therapy with prednisolone >7.5 mg/day orally or equivalent during the
             study.

          -  Non-resolution of any prior treatment related toxicity to Grade <2, except alopecia,
             vitiligo, fatigue and hypothyroidism controlled with replacement therapies.

          -  Moderate to severe immune related adverse event to prior immune-modulating agents
             within 90 days prior to the first study treatment.

          -  Central nervous system lymphoma.

          -  Prior allogeneic hematopoietic stem cell transplantation (HSCT) for patients with
             lymphoma.

          -  Autologous HSCT less than 90 days prior to initiation of study intervention.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.